Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 50090-5926

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 50090-5926). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (16cd3370 8ddc 4dbb 82b3 98e128fb3482 01)

Chemical structure diagram of memantine hydrochloride, showing its bicyclo[2.2.1]heptane skeleton with amine (NH2) and hydrochloride (HCl) functional groups, as well as methyl substituents.*

FDA Label Image

Figure 1 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 02)

A line graph showing mean change from baseline in the ADCS-ADL score over 28 weeks of treatment. Two groups are compared: Placebo and Memantine Hydrochloride. The graph indicates clinical improvement above the baseline and clinical decline below. Data points include error bars representing SEM.*

FDA Label Image

Figure 2 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 03)

A line chart comparing the cumulative percentage of patients versus ADCS-ADL change from baseline for Memantine Hydrochloride and placebo groups. The chart shows two curves representing patient response over time, with Memantine Hydrochloride indicated by open circles and placebo by filled squares.*

FDA Label Image

Figure 3 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 04)

A line graph depicting the mean change from baseline in SIB score over 28 weeks of treatment. It compares Placebo and Memantine Hydrochloride groups, showing clinical improvement and clinical decline on the vertical axis with data points and error bars at several time intervals.*

FDA Label Image

Figure 4 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 05)

A cumulative percentage of patients chart showing SIB (Severe Impairment Battery) change from baseline on the x-axis and cumulative percentage of patients on the y-axis. Two data series are plotted: Memantine Hydrochloride (open circles) and placebo (solid squares), illustrating differences in patient response over time.*

FDA Label Image

Figure 5 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 06)

A line graph showing mean change from baseline in ADCS-ADL scores over 24 weeks of treatment. The x-axis represents weeks of treatment, and the y-axis shows mean change in scores. Two treatment groups are compared: Placebo/Donepezil and Memantine Hydrochloride/Donepezil, with error bars displayed for each data point. The graph includes horizontal lines labeled Clinical Improvement and Clinical Decline.*

FDA Label Image

Figure 6 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 07)

A cumulative percentage of patients graph comparing the effects of Memantine Hydrochloride/Donepezil versus Placebo/Donepezil. The X-axis shows ADCS-ADL change from baseline and the Y-axis shows cumulative percentage of patients, with data points for both treatment groups.*

FDA Label Image

Figure 7 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 08)

A line graph comparing the mean change in baseline ADAS-Cog scores over 24 weeks of treatment between Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups. The graph shows clinical improvement above the baseline line and clinical decline below it, with error bars indicating SEM variability at each time point.*

FDA Label Image

Figure 8 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 09)

A cumulative percentage of patients graph comparing Placebo/Donepezil and Memantine Hydrochloride/Donepezil based on SIB change from baseline. The horizontal axis represents the change from baseline in SIB scores, and the vertical axis shows the cumulative percentage of patients, illustrating the distribution of patient responses for each treatment group.*

FDA Label Image

Company Logo (16cd3370 8ddc 4dbb 82b3 98e128fb3482 10)

FDA Label Image

Label Image (Lbl500905926)

Memantine Hydrochloride 5 mg film-coated tablets carton label from A-S Medication Solutions. The label indicates oral dosage, storage at 60 to 70 degrees Fahrenheit, and contains 60 tablets. The package includes a QR code and barcodes, with lot and product number information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.